Pharma Focus Asia
KP - Choose our fully recyclable blister films

Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia

BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer.

Plinabulin is a first-in-class differentiated immune and stem cell modulator. The complementary mechanisms actions of Plinabulin and G-CSFs can prevent chemotherapy-induced neutropenia.

U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for Plinabulin in Prevention of Chemotherapy-Induced Neutropenia (CIN).

Chemotherapy-Induced Neutropenia (CIN) a common side effect is generally observed in cancer patients who are under treatment. CIN mainly destroys a type of white blood cells in a patient’s body which is considered to be the first line of defense against infections. Neutrophil, a type of white blood cell assures the patients from protecting against infectious diseases. Moreover, patients having low concentration of neutrophils may easily lead to infections, hospitalisation and death.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024